Evidence map›Paper›PMID 37365889›Full record

ArticleThoracic cancer2023

Restin protein expression in non-small cell lung cancer.

Frank Aboubakar Nana, Virginie Lamberts, Delphine Hoton, Claudia Pop Stanciu, Marylène Lecocq, François M Carlier, Fabrice Duplaquet, Lionel Pirard, Charles Pilette, Benoît Bihin and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Frank Aboubakar NanaDivision of Pulmonology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Virginie LambertsDivision of Pulmonology, CHU UCL Namur, Yvoir, Belgium.
Delphine HotonDepartment of Pathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Claudia Pop StanciuDepartment of Pathology, CHU UCL Namur, Yvoir, Belgium.
Marylène LecocqPole of Pneumology, ENT, and Dermatology (PNEU), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
François M CarlierPole of Pneumology, ENT, and Dermatology (PNEU), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
Fabrice DuplaquetDivision of Pulmonology, CHU UCL Namur, Yvoir, Belgium.
Lionel PirardDivision of Pulmonology, CHU UCL Namur, Yvoir, Belgium.
Charles PiletteDivision of Pulmonology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Benoît BihinScientific Support Unit, CHU UCL Namur, Yvoir, Belgium.
Sebahat OcakPole of Pneumology, ENT, and Dermatology (PNEU), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.ORCID 0000-0002-7894-1113
CHU Dinant Godinne UCL Namur · BECliniques Universitaires Saint-Luc · BEUCLouvain · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRestin is a member of the melanoma-associated antigen (MAGE) superfamily. Its expression has been reported to be up- or downregulated in cancer. Preclinical data suggest it is a tumor suppressor. In this study, we aimed to evaluate restin expression and prognostic value in non-small cell lung cancer (NSCLC).

methodsRestin expression was analyzed by immunohistochemistry in three tissue microarrays consisting of formalin-fixed/paraffin-embedded NSCLC specimens from 113 patients, represented in triplicate. Restin staining H-score was the result of the staining intensity (0-no, 1-weak, 2-moderate, and 3-strong) multiplied by the percentage of stained tumor cells; it was defined as low if 1-100, moderate if 101-200, and strong if 201-300. Haverage-score was the average H-score in the triplicate. Restin Haverage-scores were tested for correlations with clinical and pathological characteristics and patient outcome.

resultsRestin expression was localized to the cytoplasm, with nuclear enhancement, of 112/113 (99.1%) NSCLCs. Restin Haverage-scores were 0 in 1/113 (0.88%), low in 15/113 (13.3%), moderate in 48/113 (42.5%), and strong in 49/113 (43.4%) NSCLCs. Restin Haverage-scores did not correlate with NSCLC histological subtype, disease stage, recurrence/progression-free, or overall survival.

conclusionRestin is moderately to strongly expressed in the majority of NSCLC tumors but its expression has no prognostic value in patients with NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansMicrotubule-Associated ProteinsNeoplasm ProteinsPrognosiscytoplasmic linker protein 170Microtubule-Associated ProteinsNeoplasm ProteinsexpressionimmunohistochemistryNSCLCprognosisrestin

Identifiers

PMID37365889
PMCPMC10423652
OpenAlexW4382181984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.